As of 2024-12-12, the Intrinsic Value of Newron Pharmaceuticals SpA (NWRN.SW) is (23.70) CHF. This NWRN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7.72 CHF, the upside of Newron Pharmaceuticals SpA is -406.90%.
The range of the Intrinsic Value is (160.24) - (13.81) CHF
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (160.24) - (13.81) | (23.70) | -406.9% |
| DCF (Growth 10y) | (16.56) - (194.11) | (28.57) | -470.1% |
| DCF (EBITDA 5y) | (4.62) - (6.70) | (1,146.31) | -123450.0% |
| DCF (EBITDA 10y) | (6.67) - (9.61) | (1,146.31) | -123450.0% |
| Fair Value | -4.49 - -4.49 | -4.49 | -158.20% |
| P/E | (11.43) - (18.58) | (15.48) | -300.5% |
| EV/EBITDA | (5.59) - (7.20) | (5.24) | -167.9% |
| EPV | (10.84) - (15.85) | (13.35) | -272.9% |
| DDM - Stable | (19.12) - (278.34) | (148.73) | -2026.6% |
| DDM - Multi | (13.40) - (155.98) | (24.96) | -423.3% |
| Market Cap (mil) | 150.22 |
| Beta | 1.44 |
| Outstanding shares (mil) | 19.46 |
| Enterprise Value (mil) | 188.25 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.23% |
| Cost of Debt | 5.50% |
| WACC | 5.29% |